Navigation Links
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
Date:1/31/2008

TOKYO and WOODCLIFF LAKE, N.J., Feb. 1 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) and Eisai's U.S. subsidiary, Eisai Corporation of North America (Headquarters: New Jersey, the United States, Chairman & CEO: Hajime Shimizu), today announced a change in the schedule for submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for E7389 (generic name: eribulin mesylate) for third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine.

Eisai is committed to developing E7389 as a potential treatment for patients with advanced breast cancer. In a Phase II study of 299 patients with advanced breast cancer who had been heavily pretreated, the compound has shown promising anti-tumor activity, with a response rate of 14.1% by investigator evaluation and 9.3% by independent radiologist evaluation. It has also been shown in the Phase II study to be generally well-tolerated, with the most common Grades 3 and 4 drug-related adverse events being 54% in neutropenia and 14% in leucopenia. Grade 3 peripheral neuropathy occurred in 6% of study participants, and there were no Grade 4 events.

Eisai had planned to submit an NDA under Subpart H*, based on Phase II clinical trial data, to seek accelerated approval for E7389 as a third-line breast cancer treatment (monotherapy), but is precluded from doing so, because FDA approved another drug for this specific indication last October. Eisai remains committed to advancing two Phase III clinical trials for E7389, which are ongoing in the U.S. and in Europe, Study 301 for second-line and Study 305 for third-line breast cancer treatment. Eisai now plans to submit an NDA to FDA with data from these trials and Phase II clinical trial data in fiscal year 2009-2010. In addition, Eisai continues to evaluate E7389 as a potential treatment for a variety of other solid tumors, including non-small
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
2. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 OriginOil Inc. (OTC/QB: OOIL), ... process to clean up large quantities of water, announced ... Eckelberry reported on the launch of the company's CLEAN-FRAC™ ... provided by partner STW Resources . , Immediately ... per day (bpd) and achieved a 99.8% reduction in ...
(Date:9/30/2014)... 2014 FemCap Inc., www.femcap.com  an innovator ... of a patent No: US, 8,795,248 B2 dated Aug. ... FDA clearance in the U.S., 510(K) K121857, medical device ... patent is related to its menstrual cup with a ... is releasing FemmyCycle Teen, a third menstrual cup to ...
(Date:9/30/2014)... Springfield, Mo. (PRWEB) September 30, 2014 ... participate at ISPE Boston Product Show 2014. The Boston ... has booked the 23rd annual, day-long event for Wed., ... The show promises to be the largest in ISPE ... scheduled and upward of 3,000 attendees expected. , ...
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
Breaking Biology Technology:OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2The FemmyCycle 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... DIEGO, March 20, 2012   CareFusion announced today ... Food and Drug Administration (FDA) for its new electrodiagnostic ... EDX system is a multi-modality device for monitoring and ... system. (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ...
... LAKE CITY, March 20, 2012 Remedy Informatics, the ... research, announced that Renton, Wash.-based Providence Health & ... registries for their Orthopedic Institute and Telestroke Network to ... http://photos.prnewswire.com/prnh/20120206/SF47874LOGO ) "We are excited to work ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 3
(Date:9/30/2014)... any aquatic environment on Earth, but when the climate ... to the limit. The amount of time needed to ... different species cope in the future, reveals a new ... in the scientific journal Proceedings of the Royal ... to increasing levels of greenhouse gases in the atmosphere. ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... 2012) - The many factors that contribute to how cells ... not fully understood, but researchers at Baylor College of ... intracellular membranes fuse, and in the process, created a new ... the current edition of the journal PLoS Biology . ...
... Cytori Therapeutics (NASDAQ: CYTX) announced today the publication ... Company,s European clinical trial evaluating adipose-derived stem and ... infarction (heart attack or AMI), as Research Correspondence ... of Cardiology . The APOLLO trial was a ...
... (NAS) has awarded John Waterbury, scientist emeritus in the ... the 2012 Gilbert Morgan Smith Medal. Waterbury is ... recognition of their extraordinary scientific achievements in a wide ... sciences. The recipients will be formally recognized in a ...
Cached Biology News:Membrane fusion a mystery no more 2Adipose stem cell heart attack trial data published in JACC 2WHOI's John Waterbury receives NAS Gilbert Morgan Smith Medal 2
SHEEP ANTI FLECAINIDE...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: